The global non-steroidal anti-inflammatory drugs market size is projected to exhibit a growth rate (CAGR) of 4.45% during 2025-2033. The emerging trend of self-medication and the growing consumer awareness regarding the benefits of over-the-counter (OTC) NSAIDs for pain relief represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Growth Rate 2025-2033 | 4.45% |
Non-steroidal anti-inflammatory drugs (NSAIDs) are a type of medication that is used to reduce pain, fever, and inflammation. They work by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation in the body. Some common examples of NSAIDs include aspirin, ibuprofen, naproxen, diclofenac, etc. They are typically used to treat various conditions, including headaches, menstrual cramps, dental pain, muscle pain and inflammation, osteoarthritis, rheumatoid arthritis, etc. NSAIDs are available both over the counter and by prescription and can be taken orally, applied topically as a cream or gel, or injected into a joint or muscle.
The escalating demand for NSAIDs as an adjunct treatment for managing inflammation and pain associated with chronic conditions is primarily driving the global non-steroidal anti-inflammatory drugs market. In addition to this, the expanding geriatric population and the increasing utilization of pain relief medications to manage age-related conditions, such as arthritis and osteoporosis, are also bolstering the market growth. Moreover, the emerging popularity of topical NSAIDs, including gels and creams, since they are easier to apply and have a lower risk of side effects compared to oral NSAIDs, is further creating a positive outlook for the market. Apart from this, the rising trend of self-medication and the growing consumer awareness regarding the benefits of over-the-counter (OTC) NSAIDs for pain relief are also augmenting the market growth. Additionally, the escalating preference for NSAIDs over opioids for the treatment of pain, as they are safer and less likely to cause respiratory depression, is further acting as another significant growth-inducing factor. Besides this, ongoing advancements in drug delivery technology, such as the introduction of transdermal patches and targeted drug delivery systems, are making it easier to deliver NSAIDs directly to affected areas, potentially increasing their effectiveness, and reducing side effects. This, in turn, is expected to drive the global non-steroidal anti-inflammatory drugs market in the coming years.
IMARC Group provides an analysis of the key trends in each segment of the global non-steroidal anti-inflammatory drugs market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on route of administration, disease indication, and distribution channel.
Route of Administration Insights:
The report has provided a detailed breakup and analysis of the non-steroidal anti-inflammatory drugs market based on the route of administration. This includes oral, parenteral, and topical. According to the report, oral route of administration represented the largest segment.
Disease Indication Insights:
A detailed breakup and analysis of the non-steroidal anti-inflammatory drugs market based on the disease indication has also been provided in the report. This includes arthritis, migraine, ophthalmic diseases and others. According to the report, arthritis represented the largest segment.
Distribution Channel Insights:
A detailed breakup and analysis of the non-steroidal anti-inflammatory drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy and online pharmacy. According to the report, hospital pharmacy accounted for the largest market share.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for non-steroidal anti-inflammatory drugs. Some of the factors driving the North America non-steroidal anti-inflammatory drugs market included rapid advancement of research and development activites and increasing healthcare expenditure.
The report has also provided a comprehensive analysis of the competitive landscape in the global non-steroidal anti-inflammatory drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have also been provided. Some of the companies covered include Assertio Therapeutics, Inc., AstraZenca, Bayer AG, Dr. Reddy's Laboratories Limited, Eli Lilly and Company, GSK Plc, Horizon Therapeutics Public Limited Company, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Ltd, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Routes of Administrations Covered | Oral, Parenteral, Topical |
Disease Indications Covered | Arthritis, Migraine, Ophthalmic Diseases, Others |
Distribution Channels Covered | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Assertio Therapeutics, Inc., AstraZenca, Bayer AG, Dr. Reddy's Laboratories Limited, Eli Lilly and Company, GSK Plc, Horizon Therapeutics Public Limited Company, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Ltd, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: